Prior studies determined that combinations of mutation, copy loss, or epigenetic silencing resulting in biallelic loss of BRCA1, BRCA2, PALB2, or RAD51C in breast cancers associate with signatures of HRRd, predominantly CSig3 (19, 20). This evidence concerns the gene BRCA2 and breast carcinoma.